Health Care Utilization and Costs in Type 2 Diabetes Mellitus and Their Association with Renal Impairment

References

• . US Centers for Disease Control and Prevention. National diabetes fact sheet. http://www.cdc.gov/diabetes/pubs/factsheet11.htm. Accessed October 12, 2011
   Google Scholar
• . Shogbon AO, Levy SB. Intensive glucose control in the management of diabetes mellitus and inpatient hyperglycemia. Am J Health Syst Pharm. 2010;67(10):798–805
   PubMed Web of Science ®Google Scholar
• . DCCT Research Group. Diabetes Control and Complications Trial (DCCT): results of feasibility study. Diabetes Care. 1987;10(1):1–19
   PubMed Web of Science ®Google Scholar
• . Karter AJ, Moffet HH, Liu J, . Achieving good glycemic control: initiation of new antihyperglycemic therapies in patients with type 2 diabetes from the Kaiser Permanente Northern California Diabetes Registry. Am J Manag Care. 2005;11(4):262–270
   PubMed Web of Science ®Google Scholar
• . Kuritzky L, Epstein BJ, Lavernia F. How to obtain appropriate type 2 diabetes control in the first 180 days of treatment initiation. Postgrad Med. 2010;122(3):33–42
   PubMed Web of Science ®Google Scholar
• . Nadeau DA. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. Postgrad Med. 2010;122(3):7–15
   PubMed Web of Science ®Google Scholar
• . Freeman JS. New therapeutic options: management strategies to optimize glycemic control. J Am Osteopath Assoc. 2010;110(3 suppl 2):S15–S20
   Google Scholar
• . Katon W, Russo J, Lin EH, . Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification? Psychosom Med. 2009;71(9):965–972
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3)
   Web of Science ®Google Scholar
• . Pelletier EM, Shim B, Ben—Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. Pharmacoeconomics. 2009; 27(6):479–490
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2007. Diabetes Care. 2007;30( suppl 1):S4–S41
   PubMedGoogle Scholar
• . Lin R, Zhang P, Barker LE, Chowdhury FM, Zhang X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. Diabetes Care. 2010;33(8):1872–1894
   PubMed Web of Science ®Google Scholar
• . Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31(11):2608–2617
   PubMed Web of Science ®Google Scholar
• . Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA. 2003;289(24):3273–3277
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes, 2006. Diabetes Care. 2006;29( suppl 1):S4–S42
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. KDOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. 2010. http://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm. Accessed October 12, 2011
   Google Scholar
• . Hueston WJ, Scibelli S, Mainous AG 3rd. Use of microalbuminuria testing in persons with type 2 diabetes: are the right patients being tested? J Fam Pract. 2001;50:669–673
   PubMed Web of Science ®Google Scholar
• . Weiner DE. Public health consequences of chronic kidney disease. Clin Pharmacol Ther. 2009;86(5):566–569
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. Kidney learning solutions: GFR, chronic kidney disease. http://www.kidney.org/professionals/KLS/gfr.cfm#43. Accessed October 12, 2011
   Google Scholar
• . Weiner DE. Causes and consequences of chronic kidney disease: implications for managed health care. J Manag Care Pharm. 2007;13: S1–S9
   PubMed Web of Science ®Google Scholar
• . Selby J V, Ray GT, Zhang D, Colby CJ. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care. 1997;20(9):1396–1402
   PubMed Web of Science ®Google Scholar
• . Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med. 1999;159(16):1873–1880
   PubMedGoogle Scholar
• . Health Insurance Portability and Accountability Act of 1996. Public Law 104–191, 104th Congress. http://www.cms.hhs.gov/HIPAAGenInfo/Downloads/HIPAALaw.pdf. Accessed October 12, 2011
   Google Scholar
• . Rule AD, Larson TS, Berstralh EJ, . Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med. 2004;141:929–937
   PubMed Web of Science ®Google Scholar
• . Quan H, Sundararajan V, Halfon P, . Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Medical Care. 2005;43(11):1130–1139
   PubMed Web of Science ®Google Scholar
• . US Department of Labor, Bureau of Labor Statistics. Consumer Price Index. Chained Consumer Price Index for all urban consumers (C-CPI-U) 1999–2008, Medical Care. Series ID: SUUR0000SAM. Washington, DC: US Department of Labor, Bureau of Labor Statistics, 2008. http://data.bls.gov/cgi-bin/surveymost?su. Accessed October 12, 2011
   Google Scholar
• . Frytak J F, Henk JH, Zhao Y, Bowman L, Flynn JA, Nelson M. Health services utilization among Alzheimer's subjects: evidence from managed care. Alzheimers Dement. 2008;4(5):361–367
   PubMed Web of Science ®Google Scholar
• . Basu A, Manning WG. Issues for the next generation of health care cost analyses. Med Care. 2009;47(7 suppl 1):S109–S114
   Web of Science ®Google Scholar
• . Mihaylova B, Briggs A, O'Hagan A, Thompson SG. Review of statistical methods for analysing healthcare resources and costs. Health Econ. 2011;20(8):897–916
   PubMed Web of Science ®Google Scholar
• . Blough DK, Madden C W, Hornbrook MC. Modeling risk using generalized linear models. J Health Econ. 1999;18(2):153–171
   PubMed Web of Science ®Google Scholar
• . Sobngwi E, Enoru S, Ashuntantang G, . Day-to-day variation of insulin requirements of patients with type 2 diabetes and end-stage renal disease undergoing maintenance hemodialysis. Diabetes Care. 2010;33(7):1409–1412
   PubMed Web of Science ®Google Scholar
• . National Kidney Foundation. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis. 2007;49( suppl 2):S1–S179
   PubMed Web of Science ®Google Scholar
• . Joyce AT, Iacoviello JM, Nag S, . End-stage renal disease-associated managed care costs among patients with and without diabetes. Diabetes Care. 2004;27(12):2829–2835
   PubMed Web of Science ®Google Scholar
• . Laliberté F, Bookhart BK, Vekeman F, . Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. J Manag Care Pharm. 2009;15(4):312–322
   PubMed Web of Science ®Google Scholar
• . Pereira JB. Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease. Am J Manag Care. 2002;8( 4 suppl):S122–S135
   PubMed Web of Science ®Google Scholar
• . Zanchetti A, Stella A. Cardiovascular disease and the kidney: an epidemiologic overview. J Cardiovasc Pharmacol. 1999;33( suppl 1): S1–S6
   PubMed Web of Science ®Google Scholar
• . Cohen JT, Jasimuddin SK, Tommasulo BC, . Underdiagnosis of chronic kidney disease in the nursing home population. J Am Geriatr Soc. 2009;57(6):1123–1124
   PubMed Web of Science ®Google Scholar
• . Murphree DD, Thelen SM. Chronic kidney disease in primary care. J Am Board Fam Med. 2010;23(4):542–550
   PubMed Web of Science ®Google Scholar
• . Black C, Sharma P, Scotland G, . Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess. 2010;14(21):1–184
   PubMed Web of Science ®Google Scholar
• . Palmer AJ, Valentine WJ, Chen R, . A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. Nephrol Dial Transplant. 2008;23(4):1216–1223
   PubMed Web of Science ®Google Scholar